Marco HEOR provides government health bodies with a structured environment to evaluate health technologies using HTA criteria, supporting public health coverage decisions with transparent and auditable evidence.
Some answers to questions we often receive
Yes. Marco HEOR follows the methodological guidelines of leading global HTA bodies (NICE, ICER, HTAi) and regional bodies in Latin America, ensuring internationally comparable evaluations.
Yes. Each evaluation includes full traceability of sources, criteria, and conclusions, enabling internal and external audits of the evaluation process.
Yes. Comparison with the standard of care is a core function of Marco HEOR: it generates comparative efficacy analysis, differential safety profiles, and impact on patient-relevant outcomes versus the national reference treatment.
Yes. Marco HEOR can structure the evaluation process for candidate drugs to be incorporated into the national formulary, generating the technical reports required for the decision-making process.
Yes. Marco HEOR can structure evaluations of medical devices and procedures under the same methodological frameworks applied to drugs, with adaptations for the specific characteristics of each type of health technology.
Yes. Having rigorous HTA evaluations generated with Marco HEOR strengthens the government's negotiating position in pricing processes and access agreements with the industry, backing each decision with structured evidence.
Governments need rigorous and transparent processes to decide which treatments to incorporate into the public health system, especially for high-cost oncology drugs.
